Identifying and testing a new antibody treatment for Duchenne Muscular Dystrophy.
Official title: LEAD CANDIDATE IDENTIFICATION PK AND TOXICOLOGY STUDIES FOR ANTIBODY PROJECT IN BLUEPRINT NEUROTHERAPEUTICS (BPN) BIOLOGICS PROGRAM
Funded at Advanced Bioscience Laboratories, INC. · NIH-11212628 · Data updated 2026-11-12
This study is looking at a new treatment for Duchenne Muscular Dystrophy (DMD) using a special type of antibody, and it aims to make sure the drug is safe and works well before it can be tested in people like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Advanced Bioscience Laboratories, INC. NIH-funded |
| Lab location | 1 site (Kensington, United States) |
| Project start | July 19, 2024 |
| Project end | July 18, 2026 |
| Funding year | 2024 |
| Award (this year) | $497,895 |
| NIH project number | 75N95022D00023-0-759502400003-1 |
| Project ID | NIH-11212628 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Duchenne Muscular Dystrophy or related conditions.
✕Less likely to help
Patients with other forms of muscular dystrophy or unrelated neuromuscular disorders may not benefit from this research.
What this research studies
This research focuses on developing and testing a monoclonal antibody aimed at treating Duchenne Muscular Dystrophy (DMD). It involves pharmacokinetic studies to understand how the drug behaves in the body and toxicology studies to ensure its safety. The goal is to gather the necessary data to support an Investigational New Drug (IND) application, which is a crucial step before clinical trials can begin. Patients may be involved in future phases once the drug is deemed safe and effective.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option for patients with Duchenne Muscular Dystrophy, potentially improving their quality of life.
How similar studies have gone: Previous research has shown promise in developing monoclonal antibodies for similar conditions, indicating a potential for success in this approach.
Where this research is happening
-
Advanced Bioscience Laboratories, INC.
Kensington, United States Active
Researchers
- Principal investigator: Reddy, Kumar — Advanced Bioscience Laboratories, INC.
- Study coordinator: Reddy, Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.